Methods for treating diseases of the lung

• US 10,227,289 B2
• Filed: 05/06/2011
• Issued: 03/12/2019
• Est. Priority Date: 05/07/2010
• Status: Active Grant

• Current Assignee: Theragenics Corporation (Juniper Investment Co. LLC)
• Original Assignee: Medicus Biosciences, LLC
• Inventors: Askari, Syed H., Horng, George
• Primary Examiner(s): Ricci, Craig D
• Application Number:
  US13/696,028
• Publication Number:
  US 20130108711A1
• Time in Patent Office: 2,867 Days
• Field of Search: None
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 49/04 X-ray contrast preparations
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07C 229/24 having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
• CPC Class Codes: C08G 65/34 from hydroxy compounds or their metallic derivatives C08G65/26 takes precedence

Abstract

Provided herein are methods of treating diseases of the lung in a mammal, including cancer of the lung, mesothelioma, emphysema, and bronchopleural fistula. The methods comprise delivering a biocompatible hydrogel polymer optionally comprising a therapeutic agent directly to a target site using a minimally invasive delivery device, wherein the biocompatible hydrogel polymer gels at the target site.

Claims

1. A method of treating a lung disease in a mammal, comprising delivering a biocompatible hydrogel polymer to a target site in the lung of the mammal, wherein the biocompatible hydrogel polymer gels to at the target site in the lung and wherein the biocompatible hydrogel polymer consists of an aqueous buffer, a therapeutic agent, and a polymer prepared from monomers consisting of:

(a) 8-ARM-20k-NH2 PEG amine, 4-ARM-20k-AA acetate amine, and 8-ARM-PEG-SG monomer;

or

(b) 8-ARM-20k-NH2 PEG amine, 8-ARM-20k-AA acetate amine, and 8-ARM-PEG-SG monomer and wherein the biocompatible hydrogel polymer dos not contain blood or protein.

2. The method of claim 1, wherein the lung disease is a cancer of a lung, wherein the target site in the lung of the mammal is a site of the cancer of the lung, and wherein the therapeutic agent is an anticancer agent.

3. The method of claim 1, wherein the lung disease is mesothelioma, wherein the target site in the lung of the mammal is a site of the mesothelioma, and wherein the therapeutic agent is an anticancer agent.

4. The method of claim 1, wherein the lung disease is emphysema, wherein the target site in the lung of the mammal is a site affected by the emphysema, wherein the therapeutic agent is an antiviral agent, antibacterial agent, antifungal agent, immunosuppressant agent, or anti-inflammatory agent, wherein the biocompatible hydrogel polymer blocks an air passage or changes the lung surface tension, and wherein a portion of the lung is controllably collapsed.

5. The method of claim 1, wherein the lung disease is a bronchopleural fistula, wherein the target site in the lung of the mammal is a site of a fistula in the lung of the mammal, wherein the therapeutic agent is an antiviral agent, antibacterial agent, antifungal agent, immunosuppressant agent, or anti-inflammatory agent, wherein the biocompatible hydrogel polymer gels at the site of the fistula, and wherein the biocompatible hydrogel polymer seals the fistula.

6. The method of claim 2, wherein the anticancer agent is selected from the group consisting of docetaxel, paclitaxel, carboplatin, cisplatin, oxaliplatin, satraplatin, etoposide, gemcitabine, pemetrexed, diphtheria toxin, adenylate cyclase toxin, verotoxin-1, α

-toxin, α

-hemolysin, curare, and α

-cobratoxin.

7. The method of claim 3, wherein the anticancer agent is selected from the group consisting of docetaxel, paclitaxel, carboplatin, cisplatin, oxaliplatin, satraplatin, etoposide, gemcitabine, pemetrexed, diphtheria toxin, adenylate cyclase toxin, verotoxin-1, α

-toxin, α

-hemolysin, curare, and α

-cobratoxin.

8. The method of claim 1, wherein the biocompatible hydrogel polymer does not contain biological materials.

9. The method of claim 1, wherein the biocompatible hydrogel gels to at the target site in the lung and has a degradation time of more than 60 days.